Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Comprehensive evaluation of endoscopic fundoplication using the EsophyXTM device

  • 212 Accesses

  • 14 Citations



There are limited studies that evaluate the efficacy of endoscopic fundoplication (EF) for gastroesophageal reflux disease (GERD) with the EsophyXTM device, especially with the most recent procedural iteration (TIF-2). This study was a prospective evaluation of our early experience with this device and procedure.


Data were collected prospectively on 23 consecutive patients undergoing EF (March 2009 to August 2010). All patients completed a symptom questionnaire assessing frequency and severity of gastrointestinal and respiratory symptoms, 24-h pH, and manometry studies preoperatively and were encouraged to repeat these at 6 months.


All patients had abnormal pH studies and were on proton-pump inhibitor (PPI) therapy prior to EF. Median age was 47 years (19–62 years), and six (23%) were male. Nine (41%) patients had Body Mass Index (BMI) ≥30 kg/m2, and three (14%) had a small hiatal hernia (≤2 cm). The procedure was aborted in two patients for retained food. Three patients underwent subsequent laparoscopic Nissen fundoplication for persistent or recurrent symptoms. Median hospitalization was 1 day, and there were no major perioperative complications. At 6 month follow-up, 19 (86%) patients completed a symptom questionnaire, and 14 (64%) and 11 (50%) patients underwent pH and manometry studies, respectively. There was a significant reduction in heartburn (P = 0.02), total percentage acid contact time (P = 0.002), DeMeester score (P = 0.002), and PPI use (P = 0.003). Overall, 8 out of 14 (57%) patients had abnormal pH studies and 11 out of 19 (58%) remained on PPI therapy at 6 months.


EF with EsophyXTM is associated with significant reduction in heartburn and abnormal acid exposure at 6 months, although the majority of patients did not experience normalization of their pH studies and remained on PPI therapy. The procedure has an acceptable safety profile, but the question remains as to whether it is effective enough to warrant a place in the armamentarium for the treatment of GERD.

This is a preview of subscription content, log in to check access.

Fig. 1


  1. 1.

    El-Serag HB (2007) Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 5:17–26

  2. 2.

    Pearl JP, Marks JM (2007) Endolumenal therapies for gastroesophageal reflux disease: are they dead? Surg Endosc 21:1–4

  3. 3.

    Chen D, Barber C, McLoughlin P, Thavaneswaran P, Jamieson GG, Maddern GJ (2009) Systematic review of endoscopic treatments for gastro-oesophageal reflux disease. Br J Surg 96:128–136

  4. 4.

    Falk GW, Fennerty MB, Rothstein RI (2006) American Gastroenterological Association Institute medical position statement on the use of endoscopic therapy for gastroesophageal reflux disease. Rev Gastroenterol Mex 71:512–543

  5. 5.

    Cadiere GB, Buset M, Muls V et al (2008) Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg 32:1676–1688

  6. 6.

    Cadiere GB, Van Sante N, Graves JE, Gawlicka AK, Rajan A (2009) Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX. Surg Endosc 23:957–964

  7. 7.

    Hoppo T, Immanuel A, Schuchert M et al (2010) Transoral incisionless fundoplication 2.0 procedure using EsophyX for gastroesophageal reflux disease. J Gastrointest Surg 14:1895–1901

  8. 8.

    Velanovich V (2010) Endoscopic, endoluminal fundoplication for gastroesophageal reflux disease: initial experience and lessons learned. Surgery 148:646–651 discussion 51- 3

  9. 9.

    Bell RC, Freeman KD (2010) Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease. Surg Endosc 25(6):1975–1984

  10. 10.

    Demyttenaere SV, Bergman S, Pham T et al (2010) Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population. Surg Endosc 24:854–858

  11. 11.

    Bell RC, Cadiere GB (2010) Transoral rotational esophagogastric fundoplication: technical, anatomical, and safety considerations. Surg Endosc 25(7):2387–2399

  12. 12.

    Hill LD, Kozarek RA, Kraemer SJ et al (1996) The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc 44:541–547

  13. 13.

    Oelschlager BK, Quiroga E, Parra JD, Cahill M, Polissar N, Pellegrini CA (2008) Long-term outcomes after laparoscopic antireflux surgery. Am J Gastroenterol 103:280–287 quiz 8

  14. 14.

    Mahon D, Rhodes M, Decadt B et al (2005) Randomized clinical trial of laparoscopic Nissen fundoplication compared with proton-pump inhibitors for treatment of chronic gastro-oesophageal reflux. Br J Surg 92:695–699

  15. 15.

    Trus TL, Laycock WS, Branum G, Waring JP, Mauren S, Hunter JG (1996) Intermediate follow-up of laparoscopic antireflux surgery. Am J Surg 171:32–35

  16. 16.

    Watson DI, Jamieson GG, Lally C et al (2004) Multicenter, prospective, double-blind, randomized trial of laparoscopic nissen vs anterior 90 degrees partial fundoplication. Arch Surg 139:1160–1167

  17. 17.

    Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J (2000) Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 160:1810–1816

  18. 18.

    Van Pinxteren B, Numans ME, Bonis PA, Lau J (2000) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease- like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev:CD002095

  19. 19.

    Fumagalli Romario U, Barbera R, Repici A, Porta M, Malesci A, Rosati R (2011) Nissen fundoplication after failure of endoluminal fundoplication: short-term results. J Gastrointest Surg 15:439–443

  20. 20.

    Repici A, Fumagalli U, Malesci A, Barbera R, Gambaro C, Rosati R (2010) Endoluminal fundoplication (ELF) for GERD using EsophyX: a 12-month follow-up in a single-center experience. J Gastrointest Surg 14:1–6

  21. 21.

    Testoni PA, Corsetti M, Di Pietro S et al (2010) Effect of transoral incisionless fundoplication on symptoms, PPI use, and ph-impedance refluxes of GERD patients. World J Surg 34:750–757

Download references


Supported by the Byers Endowment in Esophageal Research at the University of Washington


Authors R. P. Petersen, L. Filippa, E. B. Wassenaar, A. V. Martin, and R. P. Tatum have no conflicts of interest or financial ties to disclose. Author B. K. Oelschlager has received honoraria as an educational speaker and is a coinvestigator in a clinical trial on the results of endoscopic fundoplication sponsored by Endogastric Solutions, Inc.

Author information

Correspondence to Rebecca P. Petersen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Petersen, R.P., Filippa, L., Wassenaar, E.B. et al. Comprehensive evaluation of endoscopic fundoplication using the EsophyXTM device. Surg Endosc 26, 1021–1027 (2012). https://doi.org/10.1007/s00464-011-1989-2

Download citation


  • GERD
  • Endoscopic fundoplication
  • EsophyXTM